MedTrace Logo

PD-L1 and BRAF Expression in Nasopharyngeal Carcinoma

NCT03989297 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2020-09-02

No results posted yet for this study

Summary

The prognostic value of programmed death-ligand 1 (PD-L1) and BRAF expression in nasopharyngeal carcinoma (NPC) is not well-defined. In this study the investigators investigated alterations in PD-L1, BRAF and EGFR by using immunohistochemistry analysis in a cohort of consecutively enrolled NPC patients.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

RADIATION

Radiation

Consecutive patients who were pathologically diagnosed with NPC and treated with radiation at the Kiang Wu Hospital.

Sponsors & Collaborators

  • Kiang Wu Hospital

    lead OTHER

Principal Investigators

  • Yabing Cao, MD; PhD · Kiang Wu Hospital, Department of Oncology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2019-12-01
Completion
2019-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03989297 on ClinicalTrials.gov